Metraipolis › archive › dc_58eeff5e1d15

Impact on Body Composition After Two Years of Elexacaftor-Tezacaftor-Ivacaftor Therapy in Children with Cystic Fibrosis — Europe PMC PMID:41462739

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41462739
DOI
10.3390/children12121598
License (as archived)
solo-consultazione
Archived
2026-11-08T07:22:23.107Z
SHA-256 of the archived text
7af9f452353fc98419605eb730ae692492d9e16d360e22f6f633dd8297475bff
Stable URL of this page
https://metraipolis.com/documento/dc_58eeff5e1d15

How to cite

Impact on Body Composition After Two Years of Elexacaftor-Tezacaftor-Ivacaftor Therapy in Children with Cystic Fibrosis — Europe PMC PMID:41462739 — Europe PMC (en), https://europepmc.org/article/MED/41462739 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_58eeff5e1d15 (Metraipolis archive dc_58eeff5e1d15, sha256 7af9f452353fc98419605eb730ae692492d9e16d360e22f6f633dd8297475bff)
BibTeX
@misc{dc58eeff5e1d15,
  title = {Impact on Body Composition After Two Years of Elexacaftor-Tezacaftor-Ivacaftor Therapy in Children with Cystic Fibrosis — Europe PMC PMID:41462739},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41462739},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_58eeff5e1d15; sha256 7af9f452353fc98419605eb730ae692492d9e16d360e22f6f633dd8297475bff},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41462739. Agents can read the archived copy with the MCP tool read_document.